Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of "Buy" by Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) has been assigned an average recommendation of "Buy" from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $24.43.

TEVA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Bank of America upped their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Wednesday, April 23rd.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Diversify Advisory Services LLC grew its stake in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after buying an additional 496 shares in the last quarter. US Bancorp DE boosted its holdings in Teva Pharmaceutical Industries by 6.5% in the 1st quarter. US Bancorp DE now owns 10,812 shares of the company's stock worth $166,000 after acquiring an additional 656 shares during the period. Thrivent Financial for Lutherans grew its position in Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock valued at $4,964,000 after acquiring an additional 699 shares in the last quarter. Bfsg LLC grew its position in Teva Pharmaceutical Industries by 7.8% in the first quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after acquiring an additional 790 shares in the last quarter. Finally, Townsquare Capital LLC raised its stake in shares of Teva Pharmaceutical Industries by 2.1% during the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after purchasing an additional 812 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded down $0.21 during trading on Friday, hitting $16.58. The stock had a trading volume of 12,519,318 shares, compared to its average volume of 10,002,805. The stock has a market cap of $18.79 billion, a price-to-earnings ratio of -11.43, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company's 50 day moving average price is $15.36 and its two-hundred day moving average price is $17.39. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the previous year, the business posted $0.48 earnings per share. The company's revenue was up 1.9% on a year-over-year basis. On average, sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.